REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 ...

In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff. Five of six patients (83%) ...

After the fasting, the uncomfortable cleanse and a drowsy ride home, it's a relief to have your colonoscopy screening behind you. But when the report arrives with the words "colon polyps," some ...

NEW YORK (Reuters Health) - People who have colorectal polyps removed are at high risk of having the abnormal growths recur, a new study shows. But only about half of people in the study underwent ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...

For 10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.

Patients with an average risk for colorectal cancer (CRC) are candidates for noninvasive tests, such as multitarget stool DNA (mtsDNA), whereas those with a higher risk, including those with a family ...

Doctors can provide alternative forms of screening for colon and rectal cancer but sometimes have a good reason to stick with the colonoscope. By Gina Kolata This year about 53,000 Americans are ...

SAN DIEGO — The majority of colorectal cancers (CRCs) that emerge following a negative colonoscopy and polypectomy occur prior to recommended surveillance exams, and those cases are more likely to be ...

“REC-4881, an allosteric MEK1/2 inhibitor, represents a first precision-medicine approach for the causal biology of FAP. In TUPELO, we are seeing rapid, substantial, and durable reductions in polyp ...